KaiVista Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $35.
Portfolio Pulse from Benzinga Newsdesk
KaiVista Pharmaceuticals shares rose following Jones Trading's initiation of coverage with a Buy rating and a $35 price target.
September 27, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jones Trading initiated coverage on KaiVista Pharmaceuticals with a Buy rating and set a price target of $35, leading to a rise in the stock price.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Jones Trading is a strong positive signal for investors, likely leading to increased buying interest and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100